Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including ...

"Most patients treated for small cell lung cancer experience rapid progression of disease and there is a high unmet need in the advanced setting," he added. "These interim results from the first ...

The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093) is for the use of the ADC to treat relapsed or refractory extensive-stage small-cell lung cancer (SCLC) and comes ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...